product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human Ephrin-A1 Fc Chimera Protein, CF
catalog :
6417-A1-050
quantity :
50 ug
price :
432 USD
more info or order :
citations: 17
Reference
Rajachandran S, Zhang X, Cao Q, Caldeira Brant A, Zhang X, Song Y, et al. Dissecting the spermatogonial stem cell niche using spatial transcriptomics. Cell Rep. 2023;42:112737 pubmed publisher
Teo L, Boghdadi A, Homman Ludiye J, Mundiñano I, Kwan W, Bourne J. Replicating infant-specific reactive astrocyte functions in the injured adult brain. Prog Neurobiol. 2021;204:102108 pubmed publisher
Jukonen J, Moyano Galceran L, Höpfner K, Pietilä E, Lehtinen L, Huhtinen K, et al. Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality. Sci Rep. 2021;11:8856 pubmed publisher
Wang H, Hou W, Perera A, Bettler C, Beach J, Ding X, et al. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Rep. 2021;34:108765 pubmed publisher
Volz C, Breid S, Selenz C, Zaplatina A, Golfmann K, Meder L, et al. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep. 2020;31:107568 pubmed publisher
Lee P, Chen S, Kuo T, Lin T, Lin M, Huang J, et al. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. Oncogene. 2020;39:2724-2740 pubmed publisher
Peng Q, Chen L, Wu W, Wang J, Zheng X, Chen Z, et al. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer. Cell Death Dis. 2018;9:1146 pubmed publisher
Gu S, Fu W, Fu A, Tong E, Ip F, Huang X, et al. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs. Sci Rep. 2018;8:7377 pubmed publisher
Chu M, Zhang C. Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer. Sci Rep. 2018;8:1539 pubmed publisher
Harboe M, Torvund Jensen J, Kjaer Sorensen K, Laursen L. Ephrin-A1-EphA4 signaling negatively regulates myelination in the central nervous system. Glia. 2018;66:934-950 pubmed publisher
Mukai M, Suruga N, Saeki N, Ogawa K. EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/maturation and promote cell adhesion and protrusion formation in HL60 monocytes. BMC Cell Biol. 2017;18:28 pubmed publisher
Song W, Hwang Y, Youngblood V, Cook R, Balko J, Chen J, et al. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene. 2017;36:5620-5630 pubmed publisher
Tanaka T, Yamada H, Kuroki M, Kodama S, Tamura K, Takamatsu Y. A Modified Adenovirus Vector-Mediated Antibody Screening Method Identifies EphA2 as a Cancer Target. Transl Oncol. 2017;10:476-484 pubmed publisher
Lennon F, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton P. Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. J Biol Chem. 2014;289:24043-58 pubmed publisher
Sugiyama N, Gucciardo E, Tatti O, Varjosalo M, Hyytiäinen M, Gstaiger M, et al. EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion. J Cell Biol. 2013;201:467-84 pubmed publisher
Gordon K, Kochkodan J, Blatt H, Lin S, Kaplan N, Johnston A, et al. Alteration of the EphA2/Ephrin-A signaling axis in psoriatic epidermis. J Invest Dermatol. 2013;133:712-722 pubmed publisher
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher
product information
brand :
R&D Systems, a Bio-Techne brand
catalog number base :
6417-A1
SKU :
6417-A1-050
product name :
Recombinant Human Ephrin-A1 Fc Chimera Protein, CF
description :
The Recombinant Human Ephrin-A1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human Ephrin-A1 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
Ephrin-A1
unit size :
50 ug
category :
Proteins and Enzymes
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
species :
Human
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
observed molecular weight :
55-60 kDa, reducing conditions
theoretical molecular weight :
46 kDa (monomer)
gene symbol :
EFNA1
details of functionality :
Measured by its binding ability in a functional ELISA. When Recombinant Human (rh) EphA2 (Catalog # 3035-A2) is coated at 2 µg/mL (100 µL/well), the concentration of rhEphrin-A1 Fc Chimera that produces 50% of the optimal binding response is found to be approximately 0.6-3 ng/mL.
endotoxin note :
<0.01 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
P20827
applications :
Bioactivity
product keywords :
6417-A1, rhEphrin-A1, hEphrin-A1, carrier-free, carrier free, 6417A1, EphrinA1, Ephrin-A 1, Ephrin A1, Tyrosine Kinase
source :
NS0-derived Recombinant Human Ephrin-A1 Fc Chimera Protein, CF
USD :
423
USD 2025 :
432 USD
alt names :
B61, ECKLG, EFL1, EFL-1, EFNA1, EPH-related receptor tyrosine kinase ligand 1, ephrin-A1, EphrinA1, EPLG1TNF alpha-induced protein 4, Immediate early response protein B61, LERK1, LERK1LERK-1, ligand of eph-related kinase 1, TNFAIP4B61, Tumor necrosis factor alpha-induced protein 4, tumor necrosis factor, alpha-induced protein 4
more info or order :
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.